Davidson MaramaHon MARAMA DAVIDSON (Co-Leader—Green): Thank you very much Madam Speaker. This is my first speech on this piece of legislation through the House for the Misuse of Drugs (Pseudoephedrine) Amendment Bill. The Green Party has been very consistent and clear in why we are supporting this bill. Firstly just to get on the Hansard record what this bill is actually doing: it is changing pseudoephedrine to a class C controlled drug instead of a class B—a downgrading if you like. And so as a class C controlled drug pseudoephedrine will then be available without prescription but will have significant restrictions such as at the import and export control level.I want to acknowledge that the member Casey Costello has just also run us through some of the controls and I guess protections for drug harm that have been wrapped particularly around this piece of legislation. I too am one of the many members of this House whose direct whānau has been very dangerously impacted on by particularly the use of meth and P—and clarifying pseudoephedrine is affiliated to the danger of that drug. What has been really really clear is that a harm reduction approach therefore is the most sensible and evidence-based approach that the Government can be taking including to pseudoephedrine. We would actually like to see more of this approach from this Government.I understand in the speeches from the Government and the honourable member whose bill this is—the speeches have put up and have communicated the driver behind this bill as being more about lessening the restrictions and accessibility. What the Greens are supporting in this bill is the consistency with taking a harm reduction approach and consistency with previous positions that we have held.Where I do agree with Te Pāti Māori in terms of the harm reduction is a harm reduction approach absolutely requires that we look at the context of drug harm. It means making sure that our community wellbeing approach is prioritised therefore. That does mean to make sure that we have got adequate quality affordable housing; incomes; health services—at the very least. I do acknowledge Takutai Tarsh Kemp's speech in terms of the experience and the work that places like Manurewa Marae have trying to fill those gaps—trying to fill the wellbeing gaps. What we would like to see alongside a harm reduction approach—which actually I neglect; let me be clear it is not to follow a straight narrow criminalisation approach because that does end up impacting on low-income Māori and Pasifika communities for example. What we would like to see alongside a non-criminalisation approach to drugs is a public health approach providing more addiction supports more wellbeing supports that I've just talked about—housing social supports income etc.So yes while we support this bill in opening up access for pseudoephedrine we have different opinions as to why we are supporting this bill which are clearly about an evidence-based public health harm minimisation approach to pseudoephedrine. We look forward to this Government providing more of the environmental supports that need to go around a drug harm support. It has been shown time and time again that a criminalisation approach does not support harm reduction does not support addiction to become less harmful for people.So it is my honour to be able to state clearly in the House our position for supporting this bill. Thank you Madam Speaker.